JP2014531031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531031A5 JP2014531031A5 JP2014537362A JP2014537362A JP2014531031A5 JP 2014531031 A5 JP2014531031 A5 JP 2014531031A5 JP 2014537362 A JP2014537362 A JP 2014537362A JP 2014537362 A JP2014537362 A JP 2014537362A JP 2014531031 A5 JP2014531031 A5 JP 2014531031A5
- Authority
- JP
- Japan
- Prior art keywords
- assay method
- competitive assay
- analyte
- capture
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 63
- 230000036963 noncompetitive effect Effects 0.000 claims description 57
- 238000012875 competitive assay Methods 0.000 claims description 56
- 239000012491 analyte Substances 0.000 claims description 46
- 239000011230 binding agent Substances 0.000 claims description 32
- 239000012528 membrane Substances 0.000 claims description 31
- 239000012472 biological sample Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 9
- 239000002359 drug metabolite Substances 0.000 claims description 7
- 108091008104 nucleic acid aptamers Proteins 0.000 claims description 7
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 108010079855 Peptide Aptamers Proteins 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 230000009918 complex formation Effects 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 4
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 4
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 4
- 229960000240 hydrocodone Drugs 0.000 claims description 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 4
- 229960001410 hydromorphone Drugs 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 229960002085 oxycodone Drugs 0.000 claims description 4
- 229960000482 pethidine Drugs 0.000 claims description 4
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims description 2
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- JGORUXKMRLIJSV-UHFFFAOYSA-N Norhydrocodone Natural products O1C2C(=O)CCC3C4CC5=CC=C(OC)C1=C5C23CCN4 JGORUXKMRLIJSV-UHFFFAOYSA-N 0.000 claims description 2
- RIKMCJUNPCRFMW-ISWURRPUSA-N Noroxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 RIKMCJUNPCRFMW-ISWURRPUSA-N 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 2
- 239000004695 Polyether sulfone Substances 0.000 claims description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 2
- 229920006243 acrylic copolymer Polymers 0.000 claims description 2
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
- 229960001736 buprenorphine Drugs 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 229960002069 diamorphine Drugs 0.000 claims description 2
- KDFWILUISXRMIK-LISRSHBKSA-N dipropanoylmorphine Chemical compound C1C2=C(C(=O)CC)C(C(=O)CC)=C(O)C3=C2[C@@]24CCN(C)[C@H]1[C@@H]4C=C[C@H](O)[C@@H]2O3 KDFWILUISXRMIK-LISRSHBKSA-N 0.000 claims description 2
- 229960004578 ethylmorphine Drugs 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- 229960002428 fentanyl Drugs 0.000 claims description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000003365 glass fiber Substances 0.000 claims description 2
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 229960001797 methadone Drugs 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- JGORUXKMRLIJSV-ZWUPXRALSA-N norhydrocodone Chemical compound O=C([C@H]1O2)CC[C@@H]3[C@@]4([H])NCC[C@@]13C1=C2C(OC)=CC=C1C4 JGORUXKMRLIJSV-ZWUPXRALSA-N 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229960005118 oxymorphone Drugs 0.000 claims description 2
- 229920000867 polyelectrolyte Polymers 0.000 claims description 2
- 229920006393 polyether sulfone Polymers 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims description 2
- 229930003945 thebaine Natural products 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims 11
- 238000004581 coalescence Methods 0.000 claims 3
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 14
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550141P | 2011-10-21 | 2011-10-21 | |
| US61/550,141 | 2011-10-21 | ||
| US201261637143P | 2012-04-23 | 2012-04-23 | |
| US61/637,143 | 2012-04-23 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075025A Division JP2017138325A (ja) | 2011-10-21 | 2017-04-05 | 小分析物の定量的検出のためのポイントオブケア免疫アッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014531031A JP2014531031A (ja) | 2014-11-20 |
| JP2014531031A5 true JP2014531031A5 (https=) | 2015-12-10 |
Family
ID=47116496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537362A Pending JP2014531031A (ja) | 2011-10-21 | 2012-10-22 | 小分析物の定量的検出のためのポイントオブケア免疫アッセイ |
| JP2017075025A Pending JP2017138325A (ja) | 2011-10-21 | 2017-04-05 | 小分析物の定量的検出のためのポイントオブケア免疫アッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075025A Pending JP2017138325A (ja) | 2011-10-21 | 2017-04-05 | 小分析物の定量的検出のためのポイントオブケア免疫アッセイ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130102003A1 (https=) |
| EP (1) | EP2769219B1 (https=) |
| JP (2) | JP2014531031A (https=) |
| AU (2) | AU2012325697B2 (https=) |
| CA (1) | CA2853103C (https=) |
| WO (1) | WO2013059805A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10101324B2 (en) | 2012-12-03 | 2018-10-16 | The Regents Of The University Of California | Non-competitive immunoassays to detect small molecules using nanopeptamers |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| CN105705938B (zh) | 2013-08-19 | 2020-11-06 | 休斯敦大学系统 | 磷光报告物 |
| US20150064672A1 (en) * | 2013-09-05 | 2015-03-05 | Matthew Bars | Systems and methods for treatment of substance addiction |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10648974B2 (en) | 2014-05-28 | 2020-05-12 | Carehealth America Corporation | Ethyl glucuronide lateral flow test strips, immunoassays, devices and methods for detecting or measuring thereof |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| GB2528657B (en) * | 2014-07-24 | 2019-03-13 | Intelligent Fingerprinting Ltd | Sample analysing device |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3256856A4 (en) * | 2014-12-17 | 2018-06-06 | Singulex, Inc. | Multiplexed single molecule analyzer |
| BR112017021305A2 (pt) * | 2015-04-06 | 2018-06-26 | Bludiagnostics Inc | dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva |
| WO2016198987A1 (en) * | 2015-06-10 | 2016-12-15 | Abs Advanced Biomedical Systems S.R.L. | Device and method for immunochromatographic assay |
| EA037478B1 (ru) | 2015-08-04 | 2021-04-01 | Дьюк Юниверсити | Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| WO2017170824A1 (ja) * | 2016-03-31 | 2017-10-05 | 積水メディカル株式会社 | 簡易免疫測定を利用した癌胎児性フィブロネクチンの検出方法 |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| EP3508851A4 (en) * | 2016-08-31 | 2020-07-29 | Sekisui Chemical Co., Ltd. | FLUORESCENT PARTICLES FOR A DIAGNOSIS AGENT AND IMMUNOLOGICAL ASSAY REAGENT USER |
| JP2020500150A (ja) | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
| WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018193592A1 (ja) * | 2017-04-20 | 2018-10-25 | 株式会社キュア・アップ | 禁煙患者のためのプログラム、装置、システム及び方法 |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| KR102582297B1 (ko) | 2017-05-19 | 2023-09-25 | 필립모리스 프로덕츠 에스.에이. | 대상체의 흡연 상태를 구별하기 위한 진단 테스트 |
| WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
| WO2019018697A1 (en) | 2017-07-19 | 2019-01-24 | Evanostics, Llc | CARTRIDGES FOR ORAL FLUID ANALYSIS AND METHODS OF USE |
| EP3665187A4 (en) * | 2017-08-08 | 2021-04-21 | OraSure Technologies, Inc. | TEST PROCEDURES FOR IMPROVED ANALYTE DETECTION |
| US11262367B2 (en) | 2017-12-15 | 2022-03-01 | Evanostics Llc | Optical reader for analyte testing |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| JP7151987B2 (ja) * | 2018-05-09 | 2022-10-12 | 株式会社Cureapp | 禁煙患者のためのプログラム、装置、システム及び方法 |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| IT201800008274A1 (it) * | 2018-08-31 | 2020-03-02 | Alifax Srl | Metodo immunometrico per analisi cliniche biologiche |
| US12594347B2 (en) | 2018-09-07 | 2026-04-07 | Duke University | Nanoparticulate drug delivery systems |
| US12066383B2 (en) | 2018-12-18 | 2024-08-20 | Aspida Dx Inc. | Optical analyte detection |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| CN114631025A (zh) * | 2019-08-29 | 2022-06-14 | 米雷亚·C·阿罗诺维茨 | 侧向流动免疫化学中的定量分析物检测 |
| CN110672834A (zh) * | 2019-09-26 | 2020-01-10 | 北京丹大生物技术有限公司 | 一种快速检测样品中铅含量的试剂盒 |
| CN112029771B (zh) * | 2019-11-13 | 2021-12-14 | 安徽省昂普拓迈生物科技有限责任公司 | 一种特异性结合哌替啶的核酸适配体及其应用 |
| WO2024173482A2 (en) * | 2023-02-14 | 2024-08-22 | North Carolina State University | Compositions and methods related to aptamer-based sensors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0232357B1 (en) | 1985-08-05 | 1991-01-30 | Rijksuniversiteit Leiden | Labelled macromolecules; a process for their preparation and their use for immunological or immunocytochemical assays |
| US5846713A (en) | 1990-06-11 | 1998-12-08 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5780228A (en) | 1990-06-11 | 1998-07-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
| US6030776A (en) | 1990-06-11 | 2000-02-29 | Nexstar Pharmaceuticals, Inc. | Parallel SELEX |
| US5795721A (en) | 1990-06-11 | 1998-08-18 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of ICP4 |
| US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US5869641A (en) | 1990-06-11 | 1999-02-09 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of CD4 |
| US6001988A (en) | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5723289A (en) | 1990-06-11 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | Parallel selex |
| US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| US5476766A (en) | 1990-06-11 | 1995-12-19 | Nexstar Pharmaceuticals, Inc. | Ligands of thrombin |
| US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US6028186A (en) | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
| US5451504A (en) * | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
| US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
| US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| US6020130A (en) | 1995-06-07 | 2000-02-01 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands that bind to and inhibit DNA polymerases |
| DE19622503C2 (de) * | 1996-06-05 | 1998-07-09 | Securetec Sicherheitstechnolog | Verfahren zum Nachweis von Analyten auf einer Oberfläche |
| US5792613A (en) | 1996-06-12 | 1998-08-11 | The Curators Of The University Of Missouri | Method for obtaining RNA aptamers based on shape selection |
| US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| FI20022048A0 (fi) * | 2002-11-18 | 2002-11-18 | Valtion Teknillinen | Ei-kompetetiivinen immunomääritys pienille analyyteille |
| US7638093B2 (en) * | 2004-01-28 | 2009-12-29 | Dnt Scientific Research, Llc | Interrupted flow rapid confirmatory immunological testing device and method |
| DE502004000540D1 (de) * | 2004-02-13 | 2006-06-14 | Brahms Ag | Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens |
| EP1733233B1 (en) * | 2004-03-30 | 2012-12-12 | GE Healthcare Bio-Sciences Corp. | Lateral flow format, materials and methods |
| EP1787121B1 (en) * | 2004-07-29 | 2010-08-25 | Relia Diagnostic Systems, LLC | Lateral flow system and assay |
| US20060127886A1 (en) * | 2004-12-15 | 2006-06-15 | Kaylor Rosann M | Sample-efficient lateral flow immunoassay |
| SG169395A1 (en) * | 2006-02-09 | 2011-03-30 | Univ South Florida | Detection of cancer by elevated levels of bcl-2 |
| JP2009529885A (ja) * | 2006-03-17 | 2009-08-27 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム酵素に対する抗体の検出のためのアッセイ |
| GB0605965D0 (en) * | 2006-03-24 | 2006-05-03 | Univ East Anglia | Fluorescence based detection of substances |
| JP4698559B2 (ja) * | 2006-11-24 | 2011-06-08 | Ｎｅｃソフト株式会社 | ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子 |
| CA2671872A1 (en) * | 2006-12-07 | 2008-06-12 | University Of Florida Research Foundation, Inc. | Materials and methods for efficient and accurate detection of analytes |
| JP2009189310A (ja) * | 2008-02-15 | 2009-08-27 | Olympus Corp | 高親和性核酸フラグメント群の塩基配列決定方法および核酸アプタマーのスクリーニング方法 |
| JP2009195187A (ja) * | 2008-02-22 | 2009-09-03 | Olympus Corp | 核酸アプタマーのスクリーニング方法 |
| AU2010248380B2 (en) * | 2009-05-15 | 2013-12-19 | Nec Solution Innovators, Ltd. | Aptamer that recognizes peptide |
| US9476891B2 (en) * | 2009-07-21 | 2016-10-25 | Sekisui Medical Co., Ltd. | Insulin assay |
| JP6041373B2 (ja) * | 2010-02-01 | 2016-12-07 | Ｎｅｃソリューションイノベータ株式会社 | ＴＮＦ−αに結合するアプタマー分子 |
-
2012
- 2012-10-22 AU AU2012325697A patent/AU2012325697B2/en active Active
- 2012-10-22 WO PCT/US2012/061354 patent/WO2013059805A1/en not_active Ceased
- 2012-10-22 CA CA2853103A patent/CA2853103C/en active Active
- 2012-10-22 US US13/657,625 patent/US20130102003A1/en not_active Abandoned
- 2012-10-22 EP EP12780383.1A patent/EP2769219B1/en active Active
- 2012-10-22 JP JP2014537362A patent/JP2014531031A/ja active Pending
-
2016
- 2016-02-04 AU AU2016200720A patent/AU2016200720A1/en not_active Abandoned
-
2017
- 2017-04-05 JP JP2017075025A patent/JP2017138325A/ja active Pending
-
2018
- 2018-12-20 US US16/227,844 patent/US20190204309A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531031A5 (https=) | ||
| Guteneva et al. | Rapid lateral flow assays based on the quantification of magnetic nanoparticle labels for multiplexed immunodetection of small molecules: application to the determination of drugs of abuse | |
| Raston et al. | A new lateral flow strip assay (LFSA) using a pair of aptamers for the detection of Vaspin | |
| AU2012325697B2 (en) | Point-of care immunoassay for quantitative small analyte detection | |
| Xiao et al. | Molecularly imprinted polymer grafted paper-based method for the detection of 17β-estradiol | |
| Gu et al. | SERS sensors: recent developments and a generalized classification scheme based on the signal origin | |
| Zhang et al. | Novel nitrocellulose membrane substrate for efficient analysis of circulating tumor cells coupled with surface-enhanced Raman scattering imaging | |
| US9599609B2 (en) | Lateral flow strip assay with immobilized conjugate | |
| Kim et al. | Surface-enhanced Raman scattering-based dual-flow lateral flow assay sensor for the ultrasensitive detection of the thyroid-stimulating hormone | |
| Fu et al. | Development of a novel dual-functional lateral-flow sensor for on-site detection of small molecule analytes | |
| CN104745585B (zh) | 甲基苯丙胺核酸适体、检测试剂盒及其应用 | |
| Lu et al. | Ultrasensitive turn on molecularly imprinted fluorescence sensor for glycoprotein detection based on nanoparticles signal amplification | |
| CN104745586B (zh) | 可卡因核酸适体、检测试剂盒及其应用 | |
| JP2013513113A5 (https=) | ||
| JP2017524140A5 (https=) | ||
| Mao et al. | Simultaneous detection of nucleic acid and protein using gold nanoparticles and lateral flow device | |
| US20160327510A1 (en) | Methods and systems for the electrochemical detection of analytes | |
| CN116136533A (zh) | 免疫层析试验片 | |
| Zhang et al. | Multivalent aptamer-linked tetrahedron DNA assisted catalytic hairpin assembly for accurate SERS assay of cancer-derived exosomes in clinical blood | |
| Vangala et al. | Simultaneous and sequential protein and organothiol interactions with gold nanoparticles | |
| Sun et al. | Oriented Antibody Functionalized Plasmonic Yolk–Shell-Satellite Nanostructures for Ultrasensitive SERS-Based Lateral Flow Immunoassay | |
| Ryu et al. | A liquid crystal–based biosensor for sensitive detection of tumor necrosis factor-alpha | |
| WO2018146534A1 (en) | Methods and biosensors for tumor detection | |
| US20120183980A1 (en) | Kit for amplifying detected signal in immunosensor and method for detecting target antigen using the same | |
| JP2008096189A (ja) | 蛍光測定法と、蛍光測定のための測定用チップ及びその製造方法 |